Interleukin-13: A promising therapeutic target for autoimmune disease |
| |
| Affiliation: | 1. School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia;2. Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden;3. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia;4. Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, UP, India;5. Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia;6. School of Life Sciences, Faculty of Science, University of Technology Sydney, NSW 2007, Australia;7. Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia;8. Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia |
| |
| Abstract: | Interleukin-13 (IL-13) was previously thought to be a redundant presence of IL-4, but in recent years its role in immunity, inflammation, fibrosis, and allergic diseases has become increasingly prominent. IL-13 can regulate several subtypes of T helper (Th) cells and affect their transformation, including Th1, Th2, T17, etc., thus it may play an important role in immune system. Previous studies have revealed that IL-13 is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), etc. In this review, we will briefly discuss the biological features of IL-13 and summarize recent advances in the role of IL-13 in the development and pathogenesis of autoimmune diseases. This information may provide new perspectives and suggestions for the selection of therapeutic targets for autoimmune diseases. |
| |
| Keywords: | IL-13 Autoimmune diseases Therapeutic target |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
